Advertisement
RVTY vs STE
Which Stock Would AI Choose? Revvity (RVTY) vs. STERIS (STE) Stock Comparison
Key Takeaways
- Revvity (RVTY) reported Q1 2026 revenue of $711 million, up 7% year-over-year, beating estimates, with adjusted EPS of $1.06.
- STERIS (STE) trades at a larger market cap of around $22 billion versus RVTY's $11 billion, reflecting broader scale in infection prevention.
- Year-to-date, STE has shown stronger gains at approximately 18% compared to RVTY's 4-5%, outperforming the S&P 500 in both cases.
- Both stocks lag the S&P 500 over one year, with RVTY up 9% and STE up 7-8% versus the index's 30%+.
- Recent momentum favors RVTY post-earnings with a 2%+ daily gain and 17% five-day rise, amid plans to divest China immunodiagnostics business.
- STE faces upcoming Q4 earnings on May 12, with expectations of $1.60 billion revenue and $2.89 EPS.
Introduction
This stock comparison examines RVTY and STE, two healthcare firms focused on life sciences and infection control. Revvity (RVTY) delivers health science solutions from discovery to diagnostics, while STERIS (STE) specializes in sterilization and patient safety products. Traders seeking exposure to medical devices, diagnostics, and biopharma services, as well as investors tracking relative performance in recent market activity, will find value in analyzing their business models, earnings momentum, and sector positioning. This analysis highlights key contrasts in growth drivers and market sentiment for informed stock comparison decisions.
RVTY Overview and Recent Performance
Revvity (RVTY), formerly PerkinElmer, is a global provider of health science solutions, operating in Life Sciences and Diagnostics segments. It offers instruments, reagents, software, and services for drug discovery, biomarker identification, imaging, and immunodiagnostics, serving pharma, biotech, and healthcare. With about 11,000 employees, it reported trailing twelve-month (TTM) revenue of approximately $2.9 billion.
In recent market activity, RVTY shares traded around $101, up over 2% in a recent session amid Q1 2026 results showing $711 million revenue (up 7% YoY, organic 3%) and adjusted EPS of $1.06, beating consensus. Year-to-date gains stand at 4-5%, with one-year returns near 9%, trailing the S&P 500. Sentiment has improved on strong execution and 3-4% organic growth guidance for 2026, though challenges like China reimbursement pressures and weak academic demand persist. The stock's forward P/E around 18-19 suggests growth potential.
STE Overview and Recent Performance
STERIS (STE) plc is a leading infection prevention company with segments in Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. It provides sterilization services, equipment, and surgical products to hospitals, pharma manufacturers, and research facilities worldwide, employing over 17,000. TTM revenue approximates $5.5 billion, underscoring its scale.
Recently, STE shares hovered near $207, down about 3% in a session but with YTD returns of roughly 18%, outpacing the S&P 500's 8%. One-year performance is around 7-8%, also behind the benchmark. Trading reflects caution ahead of Q4 earnings, with pressures from FX volatility, tariffs, and costs offset by Healthcare and AST growth. The firm maintains a Zacks Rank #3 (Hold), with market cap near $22 billion supporting stability in sterile processing demand.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots selected from 351 total bots, curated for superior performance in current market conditions. These bots, powered by AI/ML models, trade thousands of tickers across sectors like semiconductors, industrials, ETFs, and energy, employing diverse strategies such as trend analysis, multi-agent trading, and TP/SL corridors on timeframes from 5min to 60min. Stats highlight annualized returns up to 285%, win rates of 50-88%, and profit factors to 11.7, with examples like a space infrastructure bot at +285% annualized (72% win rate) and semiconductor strategies at +96% (64% win). Available via signal agents for copy trading or virtual/brokerage agents with risk management, they offer styles from high-win-rate to momentum rotation. Explore these top performers to enhance your trading edge in volatile markets.
Head-to-Head Comparison
RVTY and STE both serve healthcare but diverge in focus: RVTY's discovery-to-diagnostics model targets biopharma R&D growth, while STE's sterilization emphasizes essential hospital and pharma services. STE boasts nearly double the revenue ($5.5B TTM vs. $2.9B) and larger market cap ($22B vs. $11B), implying lower volatility but slower growth prospects.
Recent momentum shows RVTY rebounding post-earnings (YTD +4-5%, 1-month +9-12%), versus STE's YTD strength (+18%) but recent dips (-8% 1-month). Risks for RVTY include China exposure and instrumentation softness; STE faces FX, tariffs, costs. Sector-wise, both benefit from diagnostics/sterilization demand, but RVTY's forward P/E (18x) appears more attractive than peers, signaling relative value amid earnings beats.
Tickeron AI Verdict
Tickeron’s AI currently leans toward RVTY based on recent trend consistency from Q1 beats, organic growth outlook, and undervaluation signals at a forward P/E of 18x versus sector norms. Catalysts like China divestiture could sharpen focus, enhancing stability over STE's scale advantages amid earnings anticipation. Probabilistic edge favors RVTY for momentum traders, though STE suits defensive positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and STE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 3 FA rating(s) are green whileSTE’s FA Score has 1 green FA rating(s).
- RVTY’s FA Score: 3 green, 2 red.
- STE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 5 TA indicator(s) are bullish while STE’s TA Score has 4 bullish TA indicator(s).
- RVTY’s TA Score: 5 bullish, 4 bearish.
- STE’s TA Score: 4 bullish, 4 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а -1.50% price change this week, while STE (@Medical/Nursing Services) price change was -1.60% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.52%. For the same industry, the average monthly price growth was -4.27%, and the average quarterly price growth was -16.56%.
Reported Earning Dates
RVTY is expected to report earnings on Aug 03, 2026.
STE is expected to report earnings on Aug 10, 2026.
Industries' Descriptions
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.52% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| RVTY | STE | RVTY / STE | |
| Capitalization | 11.1B | 19.8B | 56% |
| EBITDA | 773M | 1.59B | 48% |
| Gain YTD | 2.509 | -19.402 | -13% |
| P/E Ratio | 47.62 | 25.27 | 188% |
| Revenue | 2.9B | 5.94B | 49% |
| Total Cash | 860M | N/A | - |
| Total Debt | 3.35B | 2.09B | 161% |
RVTY | STE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 89 | 67 | |
PRICE GROWTH RATING 1..100 | 32 | 62 | |
P/E GROWTH RATING 1..100 | 33 | 83 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STE's Valuation (8) in the Medical Specialties industry is in the same range as RVTY (15). This means that STE’s stock grew similarly to RVTY’s over the last 12 months.
STE's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as RVTY (100). This means that STE’s stock grew similarly to RVTY’s over the last 12 months.
STE's SMR Rating (67) in the Medical Specialties industry is in the same range as RVTY (89). This means that STE’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (32) in the Medical Specialties industry is in the same range as STE (62). This means that RVTY’s stock grew similarly to STE’s over the last 12 months.
RVTY's P/E Growth Rating (33) in the Medical Specialties industry is somewhat better than the same rating for STE (83). This means that RVTY’s stock grew somewhat faster than STE’s over the last 12 months.
| RVTY | STE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 59% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 46% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 53% |
| Advances ODDS (%) | 8 days ago 65% | 19 days ago 49% |
| Declines ODDS (%) | 22 days ago 67% | 13 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 48% | N/A |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | -0.96% | ||
| TMO - RVTY | 70% Closely correlated | -0.13% | ||
| IQV - RVTY | 65% Loosely correlated | +0.02% | ||
| A - RVTY | 65% Loosely correlated | -0.45% | ||
| CRL - RVTY | 65% Loosely correlated | -1.86% | ||
| DHR - RVTY | 64% Loosely correlated | +0.58% | ||
More | ||||